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ABSTRACT 
 
Candidates:  Lene Hansen and Rikke Thomassen 
Title:   Neurocognition in Schizophrenia: Measured with the MATRICS Consensus 
Cognitive Battery in a Young Adult Population 
Supervisor:  Associate Professor Anne- Kari Torgalsbøen 
 
Background:  The concept of recovery from schizophrenia has been reformed and now 
includes social adaptation, working abilities, and daily functioning, as well as decrease in 
symptoms. Neurocognitive deficits are often discovered in patients with schizophrenia, and 
have been connected to the course of illness and functional outcome. Still, heterogeneity 
characterises patients with schizophrenia and the various paths towards recovery are 
uncertain at present time. The purpose of this thesis was to examine whether significant 
differences in neurocognitive functioning between patients with schizophrenia and healthy 
controls could be detected with the MATRICS Consensus Cognitive Battery (MCCB). An 
additional aim was to describe the patients in terms of resilience, degree of hope, self-
efficacy, and daily functioning.  
Methods: Neurocognitive functioning was assessed with the MCCB in a group of 18 young 
adults with a recent debut of schizophrenia, and a healthy control group. Measures of 
resilience, hope, and self-efficacy were administered in the patient group. Patients were also 
interviewed on their daily functioning. 
Results: Significant differences in neurocognitive functioning between patients and controls 
were detected on half of the subtests of the MCCB. Investigation of degree of neurocognitive 
impairment in the patient group, revealed that 89.9 % show impairment when the mildest 
criteria are used, while only 22.2 % display impairment according to the strongest criteria. 
Descriptions of daily functioning revealed diversity in terms of employment or educational 
status, independent living, and relational functioning in the patient group.  
Conclusions: Despite the low number of participants in our study, significant differences 
between patients with schizophrenia and healthy controls are discovered with the MCCB. 
Our study demonstrates  heterogeneity on neurocognitive functioning and on several aspects 
of daily functioning in the patient group, which shed light on the importance of focusing on 
individual differences in order to offer tailored interventions and promote recovery.  
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INTRODUCTION 
 
Schizophrenia is a mental illness, which has traditionally been characterised as a chronic 
disease. At the beginning of the 20th century Kraepelin introduced the term “dementia praecox”, 
implying inevitable mental deterioration, and ever since, a common perspective about the 
downward course of the disease has dominated amongst scientists, clinicians, and the public 
(Kraepelin, 1971). Later Bleuler recognised periods of remission in patients with 
schizophrenia, though they were described mostly as temporal improvements (Bleuler, 1950). 
The introduction of antipsychotic treatment in the 1950’s made a better prognosis for patients 
with schizophrenia possible, and consequently the rate of outpatients with this diagnosis 
increased (Frese, Knight, & Saks, 2009). Patients were given hope of reintegration into 
society, but for many of them a decrease in positive symptoms appeared not to be sufficient 
for a successful adaptation to life outside hospitals and recovery as such (Hegarty, 
Baldessarini, Tohen, Waternaux, & Oepen, 1994; Sharma & Antonova, 2003). Despite its 
shortcomings in reaching full recovery, antipsychotic medication has continued to be the 
treatment of choice in medical health care worldwide. Nevertheless, during the last decades 
an extensive amount of research has contributed to a focus on positive outcome in 
schizophrenia (Harding, Brooks, Ashikaga, Strauss, & Breier, 1987; Harrison et al., 2001; 
Harrow, Grossman, Jobe, & Herbener, 2005; Torgalsbøen & Rund, 2002). Focusing on 
recovery and positive outcome is crucial in adjusting treatment to each individual, and giving 
hope to both patients and the people surrounding them. 
 
The concept of recovery 
Recovery is often characterised by complete absence of symptoms, and the goal of treatment 
is to cure the patient. This classical medical terminology and clinical approach are 
challenging when applied to mental illness, because the presence and absence of symptoms 
are neither as distinct nor absolute as in somatic illness, and symptoms intertwine with 
normal life experiences (Andreasen et al., 2005; Lieberman et al., 2008). Recently the view 
of recovery from schizophrenia has changed, and is now a wider concept focusing on social 
adaptation, working abilities, and daily functioning, as well as a decrease in symptoms (Frese 
et al., 2009). This new perspective may be seen as a reflection of the World Health 
Organization’s definition of health, which includes not only absence of symptoms and pain, 
but also the aspect of physical, mental, and social well-being (World Health Organization, 
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2010). One study demonstrated that as much as 40 % of patients with a diagnosis of 
schizophrenia experienced a period of recovery lasting one or more years, at one or more 
points in time (Harrow et al., 2005). Furthermore, full recovery was shown to be possible in 
patients with schizophrenia in longitudinal studies carried out by Torgalsbøen and Rund 
(2002), though full recovery was also somewhat rare and an unstable state, with occasions of 
recurrence of the illness. Jobe and Harrow (2005) examined the heterogeneity in outcome of 
patients diagnosed with schizophrenia, and found that schizophrenia is a mental illness with a 
relatively poor outcome. At the same time, the researchers discovered subgroups that 
experienced extended periods of recovery, supporting diversity to some extent in outcome in 
this patient group.  
 
Due to the considerable number of patients who experience remission and recovery, many 
questions have been raised concerning what factors recovery depends upon. Biological, 
psychological, and social factors have been investigated, including level of neurotransmitter 
substances, level of expressed emotions in the family environment, social support, and coping 
skills (Combs & Mueser, 2007). Cognitive functioning has been closely linked to functional 
outcome in schizophrenia, and is yet another factor generating a lot of interest from both 
scientists and clinicians (Green, 1996). The failure to reintegrate the patients suffering from 
this mental illness to a life outside mental health institutions constitutes an enormous cost for 
society. Researchers are now interested in improving functional outcome through 
neurocognition, and thereby improve patients’ quality of life and reduce societal costs 
(Sharma & Antonova, 2003). Accordingly, Helldin et al. (2006) demonstrated differences in 
cognitive abilities in favour of the patients in remission, suggesting cognitive function as a 
possible predictor of remission. There is also a new interest in neurocognitive deficits as 
target of treatment in schizophrenia, due to the link to functional outcome and recovery 
(Gold, 2004; Green & Nuechterlein, 1999). Research on the role of cognition in 
schizophrenia is important to develop both medical and psychological treatment, as well as 
generating knowledge concerning prognosis, remission, and recovery (Green, Kern, & 
Heaton, 2004; Sharma & Harvey, 2000a).  
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Neurocognition in Schizophrenia 
Clarification of terms 
Initially, schizophrenia has been considered a disorder of language and thought. The term 
cognition was introduced to describe the information processing deficits experienced by 
people suffering from the illness. As neuropsychological tests became common methods 
within the field of research on cognition and schizophrenia, the deficits were also called 
neuropsychological. However, many professionals claimed such a phrasing should be 
reserved for a methodological purpose, resulting in a new term, neurocognitive deficits 
(Green, 1998; Rund, 2002). The term neurocognition also makes the link between cognitive 
functions and neural structures more explicit, while at the same time accepting that the 
specific connections remain uncertain (Green, 1996). In this thesis we will therefore use the 
term neurocognitive when describing the impairments observed in patients with 
schizophrenia. 
 
Neurocognitive impairments as core features of schizophrenia 
Neurocognitive deficits have been associated with the diagnosis of schizophrenia for many 
years, but the implications of the deficits and how they covariate with schizophrenia have not 
yet reached a consensus. A constantly growing amount of research demonstrates that the 
patient group diagnosed with schizophrenia often has a neurocognitive function characterised 
by broad impairments (Bilder et al., 2000; Green, 1998; Heinrichs & Zakzanis, 1998; Sharma 
& Antonova, 2003; Weickert et al., 2000). Studies have shown that patients with 
schizophrenia score significantly lower on neurocognitive measures in comparison with a 
healthy control group (Hoff et al., 1999; Mesholam-Gately, Giuliano, Goff, Faraone, & 
Seidman, 2009). Also when compared to other patient groups, patients with schizophrenia 
show significantly larger impairments on measures of different neurocognitive domains. 
Patients with schizophrenia demonstrate greater deficits in executive function when 
compared to patients with bipolar disorder, suggesting that these deficits are specific to 
schizophrenia and a core feature of the illness (Wobrock et al., 2009). In addition, general 
memory impairments were discovered in patients with schizophrenia, related to both verbal 
and visual measures, while only deficits in measures of visual memory were specific to 
schizophrenia, when compared to participants with Attention Deficit Hyperactivity Disorder 
(ADHD) (Øie, Sundet, & Rund, 1999).  
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Neurocognitive impairments are considered core features and independent variables of 
schizophrenia (Nuechterlein, Green, & Kern, 2009). Studies have shown that neurocognitive 
deficits are persistent over time and across the state of symptoms. In the review of several 
longitudinal studies, Rund (1998) found that neurocognitive deficits were relatively stable 
over long periods of time after the onset of the illness. Others have found that performance on 
some neurocognitive measures remains impaired whether the symptoms are active or under 
control, and even when the patients are in remission (Kurtz, 2005). Censits et al. (1997) 
found no change in neurocognitive test performance, despite introduction of antipsychotic 
medication and symptom reduction. The assumption that neurocognitive deficits might occur 
independently of symptoms and psychopharmacological treatment is therefore supported by 
empirical evidence. Hence, neurocognitive deficits appear to be, not merely a bi-product of 
other symptoms or psychopharmacological treatment, but rather independent features.  
 
Scientists have taken an interest in how early one can detect neurocognitive differences 
between persons at risk of developing schizophrenia and their peers not at risk. By tracking 
down school records of grades from the first to twelfth grade, Bilder et al. (2006) detected 
that persons who later developed schizophrenia, performed more poorly than their fellow 
classmates, as early as the first year of school. This difference was maintained, and even 
increased, during the twelve years of schooling. Others have also found debilitated 
neurocognitive functioning from premorbid periods to first episodes of psychosis (Jahshan, 
Heaton, Golshan, & Cadenhead, 2010; Mesholam-Gately et al., 2009). But early assumptions 
of a further deterioration in the course of illness have not been supported by empirical 
evidence. Stability in neurocognitive deficits, rather than decay, has been the trend in 
longitudinal studies following patients with the diagnosis over periods of time (Hoff et al., 
1999; Jobe & Harrow, 2005; Kurtz, 2005; Rund, 1998).  
 
Moreover, researchers have been able to show that certain neurocognitive deficits could 
predict the onset of schizophrenia spectrum disorders. The genetic contribution to this illness 
has baffled scientists for several years, and the focus on genetic vulnerabilities of 
schizophrenia has recently expanded to include phenotypic indicators (Erlenmeyer-Kimling 
et al., 2000). In the New York High-Risk Study following children born to mothers suffering 
from schizophrenia, researchers found that some childhood cognitive measures could predict 
schizophrenia-related psychoses in early adulthood (Erlenmeyer-Kimling et al., 2000). In 
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addition, studies have demonstrated that neurocognitive deficits may be observed premature 
to both psychotic symptoms and other characteristics of the illness (Davidson et al., 1999). 
Research has also suggested possible specific risk markers, such as decline in working 
memory and speed of processing (Jahshan et al., 2010), as well as verbal memory deficits 
(Lencz et al., 2006). However, one should be cautious when drawing conclusions, since there 
are few longitudinal studies at the present that examine and follow high-risk individuals over 
long periods of time. 
 
Furthermore, findings indicating that neurocognitive deficits are present in an attenuated form 
amongst non-affected first-degree relatives of patients with schizophrenia emphasise the 
fundamental role of neurocognition in this mental illness (Asarnow et al., 2002). Meta-
analyses have discovered that first-degree relatives of patients with schizophrenia 
demonstrate neurocognitive deficits on several cognitive measures, corresponding to domains 
like speed of processing, attention, working memory, verbal and visual memory, as well as 
executive function (Sitskoorn, Aleman, Ebisch, Appels, & Kahn, 2004; Snitz, MacDonald, & 
Carter, 2006). Researchers assume that these findings suggest that neurocognitive deficits 
may represent an important part of genetic vulnerability in developing schizophrenia.  
 
Functional outcome is another factor closely linked to neurocognitive functioning, and 
findings suggest that neurocognitive deficits could predict functional outcome (Green, 1996; 
Green et al., 2004a). Moreover, Green et al. (2000) have identified four cognitive domains 
that covariate with functional outcome (immediate verbal memory, verbal memory, executive 
functioning, and attention/vigilance). Composite neurocognitive measures, a sum of scores on 
tests corresponding to different domains, have shown even stronger correlations to daily 
functioning. The reason for this may be that everyday functioning often requires a 
combination of several cognitive skills (Green et al., 2004a). The relationship between 
neurocognition and functional outcome is generally found to be stronger than that of 
psychotic symptoms and functional outcome (Green, 1996). Indeed, this supports the interest 
in discovering beneficial treatment of schizophrenia via neurocognition. 
 
Findings indicate that psychopharmacological treatment may improve neurocognition in 
patients with schizophrenia, such as the improvement observed when comparing the effects 
of second- versus first-generation antipsychotic medication (Harvey & Keefe, 2001; Sharma 
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& Harvey, 2000b). However, it is not certain whether the second-generation antipsychotic 
medication has an actual enhancing effect on cognition, or if the change in neurocognitive 
functioning in patients with schizophrenia is a result of reduced dosage and fewer impairing 
side effects (Carpenter & Gold 2002; Harvey & Keefe, 2001). Still, intervention through 
specific neurotransmitter agents has left scientists optimistic in developing 
psychopharmacological treatment stimulating neurocognitive functioning in schizophrenia 
(Stone, Seidman, Wojcik, & Green, 2003). Structural brain abnormalities and neural 
connectivity problems are also associated with schizophrenia, and will limit the effect of 
psychopharmacological interventions. Nevertheless, a prospect will be to develop medication 
that may enhance the efficiency of the neural systems, to improve neurocognitive functioning 
in patients with schizophrenia (Green et al., 2004b). 
 
Heterogeneity in neurocognitive functioning 
Numerous studies have shown that neurocognitive deficits are common in schizophrenia. 
Palmer et al. (1997) estimated that 90 % of the patients have clinically meaningful deficits in 
at least one cognitive domain, and as much as 70 % in two domains. The size of the 
neuropsychologically normal patient group varied from 11 to 30 %, according to the 
impairment criteria being used. Based on such findings, the amount of patients with 
schizophrenia demonstrating neurocognitive function within the normal range will fluctuate 
depending on the strictness of the criteria, but should be expected to be present to some 
extent. However, it is important to consider that even when a patient does not show 
significant impairments, their neurocognitive function may still be altered from their 
premorbid level (Green, 1998). Consonant with this, monozygotic twins diagnosed with 
schizophrenia demonstrating normal neuropsychological functioning, still performed below 
their unaffected twin on neurocognitive measures (Goldberg et al., 1990). This research sheds 
light on the heterogeneity of neurocognitive functioning in patients with schizophrenia. 
However, since a majority of patients with schizophrenia experience change in 
neurocognitive functioning, whether impairments are present or not, interventions aimed at 
enhancing cognition will still probably be beneficial. Together, this supports the necessity to 
assess cognitive function and discover ways of intervening to enhance cognition and thereby 
promote recovery (Nuechterlein et al., 2008). 
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Furthermore, suggestions have been made to implement neurocognitive deficit as a diagnostic 
criterion in the Diagnostic and Statistic Manual of Mental Disorders, Fifth Edition (DSM-V) 
(Keefe & Fenton, 2007; Lewis, 2004). The expected consequences of such a proposal would 
be a more accurate diagnosis, increased awareness amongst clinicians concerning 
neurocognitive impairments, and a more homogenous patient group. A further consequence 
of a more precise prognosis could be more efficient treatment and better outcome (Keefe & 
Fenton, 2007). On the other hand, a substantial part of the patient population will be excluded 
if such a criterion was to be introduced in DSM-V. Even though a majority of persons 
suffering from schizophrenia experience neurocognitive deficits, research indicates that up to 
30 % of the patient group will not show significant impairments in neurocognitive 
performance (Green, 1998; Palmer et al., 1997). Given the correlation between 
neurocognitive function and functional outcome, the possibility of recovery might be 
underestimated if the subgroup that shows no signs of impairment was to be excluded.  
 
Even though the group of patients with schizophrenia can be characterised as heterogenic, the 
neurocognitive difficulties experienced by the majority of patients tend to involve certain 
neurocognitive domains. Attention deficits have been considered an important part of the 
clinical picture in this illness since the beginning of the 20th century (Rund, 2002). Moreover, 
these attentional deficits have been discovered in a large scale in individuals with a diagnosis 
of schizophrenia who experience neurocognitive difficulties (Braff, 1993). Weickert et al. 
(2000) demonstrated that even the group of patients who displayed average premorbid 
intellectual levels, with no signs of decline in IQ, and a cognitive profile similar to normal, 
exhibited impairments on measures of executive function and attention. Working memory 
and memory and learning are other neurocognitive domains where patients with 
schizophrenia often struggle (Gur, Moelter, & Ragland, 2000; Keefe, 2000). Gold et al. 
(1992) discovered impairments in different areas of memory in patients with schizophrenia, 
despite the degree of attentional demands, suggesting that memory impairments are not 
necessarily dependent on impairment in other neurocognitive domains. Other leading 
scientists within the field have also supported this view of independent memory impairments 
in schizophrenia (Gur et al., 2000). 
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Social cognition 
Patients with schizophrenia often struggle in daily interactions. Relating to other persons and 
adapting to various social situations, tend to be particularly rigorous. An aspect of 
information processing associated with these difficulties is social cognition (Nuechterlein et 
al., 2004). Personal relevance and complexity of stimuli characterise the study of social 
cognition, as opposed to the stimuli used in studies of non-social cognition, often reduced to 
numbers and letters (Brekke, Kay, Lee, & Green, 2005). The complexity of stimuli in tests of 
social cognition may therefore be more ecologically valid and reveal multifaceted 
information, that is, if the measure has sound psychometric properties. It has also been 
proposed that the correlation between neurocognition and functional outcome might be 
mediated by social cognition (Brekke et al., 2005; Sergi, Rassovsky, Nuechterlein, & Green, 
2006). 
 
Specific or general deficits? 
An ongoing debate within this field of research concerns whether neurocognitive deficits in 
schizophrenia are specific to the illness or not, and if a specific pattern does exist, which 
domains are involved. Some studies examining this question have found that neurocognitive 
deficits in schizophrenia are better accounted for by a common, generalised factor, involving 
impairments across several neurocognitive domains (Dickinson, Iannone, Wilk, & Gold, 
2004; Mohamed, Paulsen, O´Leary, Arndt, & Andreasen, 1999). Other findings supporting 
non- specific impairments are studies that indicate meaningful individual cognitive 
differences within this patient group, such as the existence of a neuropsychologically normal 
subgroup (Palmer et al., 1997). Conversely, scientists have discovered distinct patterns of 
neurocognitive deficits in schizophrenia that differs significantly from that of other illnesses, 
such as depression and bipolar disorder, supporting neurocognitive deficits specific to 
schizophrenia (Green et al., 2004b; Wobrock et al., 2009). Even though a significant amount 
of research demonstrate areas of neurocognition more often affected than others in patients 
with schizophrenia, some researchers, such as Rund (2002), stress that this question still 
remains to be solved. Neurocognition has become an explicit target of treatment, which 
means that enhancement of cognition could have a significant positive effect and lead to 
recovery (Friedman, 2000; Sharma & Harvey, 2000b). If specific cognitive deficits and their 
neurobiological substrates were to be discovered, it would facilitate the development of 
effective interventions for enhancing cognition in schizophrenia. 
14 
 
The MATRICS initiative 
Reaching consensus 
Traditionally, a variety of neuropsychological tests have been used to measure neurocognitive 
functioning in patients suffering from schizophrenia. The lack of a consensus test battery for 
scientific and clinical use has made it difficult to compare results, and hampered the 
discovery of an agreement on neurocognitive difficulties specific to this group of patients. 
Therefore there have been great demands for standardised tests, sensitive to the deficits 
exhibited by patients with schizophrenia. A group of American scientists and academics from 
different areas of expertise were given the task to develop such a test battery. The process of 
developing a consensus cognitive test battery started off with the Food and Drug 
Administration (FDA) and The National Institute of Mental Health (NIMH) establishing the 
Measurement And Treatment Research to Improve Cognition in Schizophrenia initiative 
(MATRICS). The main purpose of the governmental involvement in developing a consensus 
test battery was to establish a measurement that is able to assess cognitive improvements due 
to various interventions, first and foremost medical treatment (Green et al., 2004b).  
 
The initial step in the development of the MATRICS Consensus Cognitive Battery (MCCB) 
was to identify the cognitive domains that should be included in a cognitive test battery.  
Such domains should represent separable aspects of cognition, providing more specific and 
detailed information (Nuechterlein et al., 2004). Through carefully conducted factor analyses 
and expert rankings, seven cognitive dimensions were identified and recommended for 
inclusion in the MCCB (Green et al., 2004b; Nuechterlein et al., 2008). Moreover, an 
agreement was reached on what criteria the selection of tests should be made upon, and 
which subtests that should be included (Kern, Green, Nuechterlein, & Deng, 2004). In 2005 
the battery was officially approved by the NIMH for scientific use. In addition the FDA 
recommended use of the battery in the process of developing potential cognition enhancing 
drugs for schizophrenia and related disorders. Due to the amount of interest and attention the 
work with the MATRICS initiative has received in the U.S.A., scientists in other parts of the 
world have been made aware of the potential this research might have on treatment of 
schizophrenia. 
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Norwegian research with the MCCB 
The MCCB has been translated into Norwegian, and is now used by a group of researchers 
with experience and expertise within the field of neurocognition and schizophrenia (Rund, 
Mohn, & Sundet, 2010). Since the Norwegian edition of the test battery was recently 
introduced, standardisation is still in progress and only one study using this version of the 
MCCB has been published so far. The results from this study showed significant differences 
between patient group and healthy controls on all but one neurocognitive domain (Holmén, 
Juuhl-Langseth, Thormodsen, Melle, & Rund, 2009). Social cognition, measured with the 
Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT), was the one domain in which 
no group differences were detected. This was not in line with the researchers’ expectations, 
and the use of the MSCEIT in an adolescent population was therefore questioned.  
 
Data from the Norwegian study using the MCCB also demonstrate general and explicit 
neurocognitive deficits in the patient group relative to controls. Others support these findings 
of broad neurocognitive impairment across several domains in an adolescent patient 
population (Ueland, Øie, Landrø, & Rund, 2004). The pattern of neurocognitive impairment 
discovered in adolescents with schizophrenia is similar to that found in adults sharing the 
same diagnosis. Together, these findings have left an interest in administering the MCCB on 
young Norwegian adults, to examine if the results may be replicated. 
 
Recently there has been an increased interest in first-episode psychosis and early intervention 
to promote recovery and positive outcome (Marshall & Rathbone, 2009; Simonsen et al., 
2007). The possibility of isolating different factors and decreasing their interaction with 
neurocognition, are advantageous when studying first-episode psychosis in contrast to 
patients enduring schizophrenia spectrum disorders of longer duration. Patients with several 
episodes of psychosis often have long histories of treatment and their neurocognitive function 
is therefore more likely to be influenced by effects of age, clinical symptoms, illness 
duration, and severity (Mesholam-Gately, Giuliano, Goff, Faraone, & Seidman, 2009). The 
patients included in the present study had a recent debut of psychosis and were referred to the 
study within five months after admission to hospital or outpatient clinic, to minimise the 
interference of other variables. 
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Measures of resilience, hope, and self-efficacy 
The new focus on remission and recovery in schizophrenia sheds light on several possible 
predictors of positive outcome. The main factor examined in this thesis is neurocognition, but 
at the same time it is assumed that other factors could be influential in coping with 
schizophrenia.  
 
Resilience has been demonstrated as an influential factor when coping with stressful life 
events and achieving a positive outcome after being exposed to threatening life experiences 
(Rutter, 1985). Masten, Best, and Garmezy (1990) define resilience as consisting of three 
aspects, a process, a capacity, and an outcome, which all consist of successful adaptation 
despite challenging and threatening experiences. Others refer to this concept as a measure of 
successful stress-coping abilities (Connor & Davidson, 2003). Receiving a diagnosis of 
schizophrenia, traditionally viewed as chronic, as well as experiencing negative and positive 
symptoms, neurocognitive impairments, and the immense decrease in daily functioning, 
would be expected to be experienced as major stressors. Given the expected high degree of 
experienced stress, resilience might play a significant part in coping and in functional 
outcome in schizophrenia. Researchers have shown that resilience is influenced by health 
status, demonstrating that individuals with mental illness have lower levels of resilience than 
others who do not have mental problems (Connor & Davidson, 2003). Moreover, resilience 
scores were found to be modifiable and to increase as treatment evolved. Could it be that 
resilience represents an important part of the recovery-puzzle in schizophrenia? 
 
Hope is yet another factor worth investigating in relation to prediction of functional outcome 
and recovery in schizophrenia. The concept is considered a variable of significance for 
positive daily functioning, as well as adapting to illness and promoting well-being (Herth, 
1992). Hope has been identified as a key condition in the process of restitution by individuals 
who describe themselves as being in recovery from mental illness (Jacobson & Greenley, 
2001). Research on hope in the Norwegian population revealed that the most important 
health-related variable predicting hope was self-assessed health, and that in fact a subjective 
perception of health was a stronger predictor of hope than presence of chronic disease 
(Rustøen et al., 2003).  
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When investigating patients with schizophrenia and their path towards recovery, self-efficacy 
might be of informative value. Self-efficacy is a concept reflecting an optimistic self-belief, 
and a belief that one can manage novel or difficult tasks, as well as handling the adversity of 
human functioning (Schwarzer, 1992). Suffering from schizophrenia involves a number of 
stressors, and self-efficacy is related to conscious adaptation to stressful life events and 
awareness of coping abilities in daily life. This suggests that it would be fruitful to relate the 
concept of self-efficacy to functional outcome and recovery in schizophrenia.  
 
Daily functioning 
Research on schizophrenia and recovery has been occupied with identifying factors, besides 
decrease in symptoms, contributing to a positive outcome (Green, 1996; Green et al., 2004a; 
Liberman, Kopelowicz, Ventura, & Gutkind, 2002). Moreover, outcome in schizophrenia has 
been found to be diverse and some argue that several aspects should be measured, such as 
educational and employment status, independent living, and relational functioning, in order to 
achieve sufficient information to evaluate the patients’ process of remission and recovery 
(Andreasen et al., 2005; Liberman et al., 2002). Previous findings have revealed occupational 
dysfunctions in patients with schizophrenia, documenting employment rates of 10 % and  
14.5 % at baseline level (Mueser, Salyers, & Mueser, 2001; Rosenheck et al., 2006). More 
specifically, only a minor percentage of the patient group is holding competitive jobs, despite 
expressed desire to work in the majority of the group. The loss of productivity over lifetime 
in patients with schizophrenia represents the largest indirect cost associated with the illness 
(Combs & Mueser, 2007). Research on educational status in mental illness, has found that 
living with a diagnosis is connected to reduced likelihood of achieving high levels of 
education (Kessler, Foster, Saunders, & Stang, 1995). Independent living and community 
functioning have also been studied in relation to schizophrenia, and have even been 
connected to neurocognitive deficits (Rempfer, Hamera, Brown, & Cromwell, 2003). 
Furthermore, in terms of relational functioning, studies have shown that patients with 
schizophrenia are less likely to get married and stay married, and that marital status might 
serve as a useful predictor of outcome (Agerbo, Byrne, Eaton, & Mortensen, 2004; Turner, 
Dopkeen, & Labreche, 1970). The data available in our study enable us to describe the patient 
group at baseline level on several variables of daily functioning, and will reveal if 
heterogeneity is present in the early phase of the illness. Investigation of recovery will not be 
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possible until follow-up data at a second point in time are complete, and therefore a 
prediction of outcome will not be at consideration in the present thesis. 
 
The purpose of this study 
The present study is part of an ongoing longitudinal study investigating neurocognition and 
resilience as possible predictors of recovery in the early and late course of schizophrenia, 
following the patients for ten years. Principal investigator is associate professor Anne-Kari 
Torgalsbøen, Department of Psychology, University of Oslo. The MCCB is the chosen 
neuropsychological test battery in this study, as well as consensus based definitions of 
remission (Andreasen et al., 2005) and full recovery in schizophrenia (Liberman et al., 2002). 
The collection of data is still in progress and so far 18 patients have been included in the 
study. 
 
In this thesis the Norwegian version of the MCCB will be used to examine if significant 
differences in neurocognitive functioning between patients with schizophrenia and healthy 
controls might be revealed. Based on the research previously accounted for, we expect these 
differences to take form as neurocognitive impairments in the patient group. Test 
performances of young adults with a recent schizophrenia diagnosis will therefore be 
compared with the performance of normal controls.  
 
1. The primary aim of this study is to investigate if significant differences in 
neurocognitive functioning between young adults with schizophrenia and healthy 
controls will be discovered with the MATRICS Consensus Cognitive Battery 
(MCCB).  
 
2. A subordinate purpose is to investigate what characterises young adults with 
schizophrenia in terms of resilience, hope, and self-efficacy, and to describe our 
patient group in terms of daily functioning.  
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METHODS 
 
Subjects 
The patients were recruited from mental health service institutions located in the Oslo area, 
including psychosis units at Asker and Bærum Hospital and Lovisenberg Hospital. Shortly 
after they were admitted to the institutions with a first-episode psychosis, their treating 
clinicians referred them to the longitudinal project this study is part of. Inclusion criteria were 
mental illness within the spectrum of schizophrenia and psychosis of the DSM-IV 
(schizophrenia [295.00], schizophrenia, residual type [295.60], paranoid schizophrenia [295. 
30], disorganised schizophrenia [295.10], schizophreniform disorder [295.40], schizo-
affective disorder [295.70], and psychosis unspecified [298.90]), and patients had to be 
referred within five months of their first contact with the mental health service institutions 
(APA, 1994). Furthermore, the participants had to be over the age of 18. Exclusion criteria 
were affective disorders, IQ<70, or head trauma. 
 
The final number of patients included in our study was 18, and the distribution of the 
different diagnoses was as follows: Schizophrenia n=5 (27.8 %), schizophrenia, residual type 
n=2 (11.1 %), paranoid schizophrenia n= 2 (11.1 %), disorganised schizophrenia n=1 (5.6 %), 
schizophreniform disorder n=3 (16.7 %), schizo-affective disorder n=4 (22.2 %), and 
psychosis unspecified n=1 (5.6 %). Of these, 16 (88.9 %) had started antipsychotic treatment 
before testing, and seven (38.9 %) used a combination of antipsychotic medication and 
antidepressants. Twelve of the participants in the patient group were hospitalised at the time 
of testing, and therefore the interview and the tests had to be administered at the hospital. The 
remaining six were outpatients, received treatment as outpatients, and were tested at their 
respective clinics. All patients but three had Norwegian as their mother tongue, though 
everyone was able to complete the interview and tests in Norwegian. Years of education 
varied from 9 to 16 (M 11, SD 2).  
 
In the control group, the youngest subjects were recruited from Junior- and Senior High 
schools in the Oslo metropolitan area. The older part of the group replied to advertisements 
on a hospital trust internet homepage (Vestre Viken Hospital Trust) and a health information 
webpage (nettdoktor.no). The control group was tested at Asker and Bærum Hospital or the 
Department of Psychology at the University of Oslo. They were matched to the patient group 
20 
 
on gender, age and education. In relation to mental health, the participants in the control 
group were either screened for mental problems using the Mini-International-
Neuropsychiatric-Interview (MINI) (Sheehan et al., 1998), or asked a non-standardised set of 
questions on mental health. 
 
After carefully describing the study and the procedures involved, written informed consent 
were obtained from participants in both patient and control group. Testers also made sure that 
the patient group was made fully aware of what their role, as participants in this study, would 
involve. The study has been approved by the Regional Committee for Medical Research 
Ethics (REK). 
 
Clinical instruments 
The clinical interviews and tests were carried out by experienced clinicians, trained in the use 
of the different instruments. For establishment of diagnosis, the participants were interviewed 
with the Structural Clinical Interview for DSM-IV (SCID) (First, Spitzer, Gibbon, & 
Williams, 1996). SCID was used in order to establish a diagnosis on the first axis, with the 
modules A-E. The degree of symptoms and psychopathology was measured with the Positive 
and Negative Syndrome Scale (PANSS) for schizophrenia (Kay, Fiszbein, & Opler, 1987). In 
some cases, after patients had given their consent, additional information was obtained from 
therapists and first-degree relatives.  
 
Furthermore, information on resilience, hope, and self-efficacy was obtained from subjects in 
the patient group, using self-report forms. In order to assess degree of resilience, a Norwegian 
translated and back-translated version of the Connor-Davidson Resilience Scale (CD-RISC) 
was chosen (Connor & Davidson, 2003). The scale consists of 25 items each rated on a five-
point scale (0-4), with higher scores reflecting a greater degree of resilience. A mean score of 
80.4 (SD 12.8) was discovered in the general population and 68.0 (SD 15.3) in a group of 
outpatients with mental illness. Our patient group will be compared according to these 
findings. In developing this scale, Connor and Davidson discovered that Cronbach’s α was 
.89. Test validity was documented by positive correlations to measures of hardiness and 
social support, and negative correlations to measures of perceived stress, stress vulnerability, 
and disability.  
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Measuring the subjects’ perceived degree of hope, the Norwegian version of the Herth Hope 
Index (HHI) was selected (Herth, 1992; Rustøen et al., 2003). This scale comprises 12 items 
each rated on a four-point Likert scale (from “strongly agree” to “strongly disagree”). A 
mean score of 36.7 (SD 4.1) was detected in the general population and will be the basis for 
comparison in our study (Rustøen et al., 2003). Herth (1992) demonstrated a Cronbach’s α of 
.97, indicating high degree of internal consistency. Moreover, convergent validity was 
discovered with measures of existential well-being and hope, and divergent validity was 
found with measures of hopelessness.  
 
The degree of perceived self-efficacy was assessed using the Norwegian version of The 
General Perceived Self-Efficacy Scale (GSE) (Røysamb, Schwarzer, & Jerusalem, 1998). 
The scale is composed of ten items, each rated on a four-point Likert scale (from “completely 
wrong” to “completely right”). A mean score of 29.6 (SD 5.3) was discovered in a total 
sample from 25 countries and will be used to discuss the level of self-efficacy in our patient 
group (Scholz, Gutiérrez-Doña, Sud, & Schwarzer, 2002). Reliability was also investigated, 
and Cronbach’s α ranged from .75 to .91. Documenting test validity, positive correlations to 
favourable emotions, dispositional optimism, and work satisfaction were found. Furthermore, 
negative correlations to variables such as depression and health complaints, were also 
discovered. To sum up, the CD-RISC, the HHI, and the GSE all have sound psychometric 
properties and are able to distinguish between those with greater and lesser degree of 
resilience, hope, and self-efficacy. 
 
A semi-structured interview was used to assess educational and employment status, 
independent living (grocery shopping, domestic chores, leisure activity, and housing 
situation), as well as relational functioning (friends, family, and partner). These aspects of 
psychosocial functioning are part of the consensus based recovery criteria used in the main 
study (Liberman et al., 2002). 
 
Neurocognitive instruments 
Neurocognitive assessment was carried out by either clinical psychologists, or graduate 
students of psychology, trained in administering standardised neuropsychological tests. 
Intellectual abilities were assessed using four subtests of the Wechsler Adult Intelligence 
Scale Third Edition (WAIS-III) (vocabulary, similarities, block design, and matrix reasoning) 
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(Wechsler, 2003). The Norwegian version of the MCCB was used to assess neurocognitive 
function (Nuechterlein & Green, 2009). This test battery consists of ten tests measuring the 
following seven neurocognitive domains; speed of processing, attention/vigilance, working 
memory, verbal learning, visual learning, reasoning and problem solving, and social 
cognition. 
 
Speed of processing  
Three tests are used to measure the subjects’ speed of processing. The Trail Making Test part 
A (TMT-A) measures how rapidly participants are able to draw a connection between 
numbers placed randomly on a piece of paper (Army Individual Test Battery, 1944). The 
faster the task is completed, the higher the score. In the following test, the Brief Assessment 
of Cognition in Schizophrenia (BACS), the task is to connect unique symbols with 
corresponding numbers, by referring to an explanation key (Keefe, 1999). The symbols are 
arranged in lines across a sheet in a random sequence, and participants must find the 
corresponding number using the explanation key. The final test of speed of processing is the 
Category Fluency Test in which the participants are to name as many animals as they 
possibly can in 60 seconds (Spreen & Strauss, 1991).  
 
Attention/vigilance 
The chosen test for assessing attention in the MCCB is the Continuous Performance Test 
Identical Pairs (CPT-IP) (Cornblatt, Risch, Faris, Friedman, & Erlenmeyer-Kimling, 1988). 
This is the only test administered on a computer. When the participants discover two identical 
numbers flashing on the screen in a row, they should respond as quickly as possible by 
pressing the left mouse button. There are three different conditions in the CPT-IP; two, three, 
and four digit numbers. Monitoring the numbers is the final task in the test battery, lasting for 
ten minutes. 
 
Working memory 
To measure working memory the participants complete two different tests, verbal and visual. 
The University of Maryland- Letter-Number Span (LNS) is the test assessing the verbal part 
of working memory (Gold, Carpenter, Randolph, Goldberg, & Weinberger, 1997). Numbers 
and letters are orally presented to the participants and their task is to organise the information, 
sorting numbers from letters, and presenting the numbers in an ascending order, and the 
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letters alphabetically. The visual part of working memory is measured with the Spatial Span 
(Wechsler Memory Scale III) (Wechsler, 1997). The administrator presents a visual pattern 
by touching blocks on a board, and the participants have to repeat this pattern by touching the 
board in the exact same order. There are two conditions, forwards and backwards, either to 
repeat the tapping in the same order as the administrator, or to reverse the pattern.  
 
Verbal learning and memory 
In the Hopkins Verbal Learning Test-Revised (HVLT-R) a list of twelve words are read out 
loud to the participants and they have to repeat as many words as they are able to remember 
immediately after the words have been presented (Brandt & Benedict, 2001). This procedure 
is repeated three times, which makes it possible to study the learning effects between the 
trials.  
 
Visual learning and memory 
The Brief Visuospatial Memory Test- Revised (BVMT-R) exposes participants for visual 
stimuli for ten seconds (Benedict, 1997). Six different figures printed proportionally on a 
piece of paper are held up in front of the participants. The respondents are supposed to 
remember the accurate place and the shape of the figures, then draw the figures as thoroughly 
as they possibly can. They are rewarded for accuracy and correct location. To discover visual 
learning effects, the BVMT-R is carried out in three trials.  
 
Reasoning and problem solving 
In the Mazes Test (Neuropsychological Assessment Battery-NAB) the participants have to 
complete seven mazes with gradually increasing difficulty (White & Stern, 2003). The mazes 
are printed on paper and completed with a pencil. Participants are rewarded for solving the 
mazes rapidly, since scores are based on the total time used on all seven mazes.  
 
Social cognition 
When measuring the domain of social cognition the MSCEIT, part D and H, is used (Mayer, 
Salovey, & Caruso, 2002). Participants are exposed to stories of various social situations, and 
have to evaluate the consequences of different actions. The text is read aloud, and the 
participants also have a copy of the text in front of them. Scores from the test were calculated 
using general consensus scores and computed into the MCCB scoring program.   
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Statistical analyses 
Data analyses were done using the statistical package SPSS for Windows (version 16.0). All 
tests were two-tailed and the level of significance was set to p= .05. To examine and compare 
the neurocognitive performance of patients with schizophrenia and healthy controls, the 
applied method was independent samples t-test. Furthermore, resilience, hope, and self-
efficacy, and variables of daily functioning, were portrayed using descriptive statistics and 
frequencies. 
 
Data analyses were carried out using raw scores from neurocognitive measures. Standardised 
American norms for the youngest part of the group (<20 years of age) are missing, and the 
process of developing standardised Norwegian norms is still in progress. This lack of norms 
made it a necessity to use raw scores for data analyses in this thesis. Consequently, raw 
scores on single neurocognitive tests were analysed separately because a comparison of 
domains was impossible. Another consequence following the lack of standardised norms was 
the inability to use composite scores to comment on the overall neurocognitive functioning, 
as well as analysing the correlation between neurocognition and daily functioning. 
Controlling for the impact of premorbid differences in intellectual functioning was also 
prevented, since such an analysis would involve standardised scores from the WAIS-III and 
the MCCB.  
 
To characterise the distribution of impairment within the patient group, a cut-off score of 1.0 
SD below the mean score of the control group was used as a threshold for “moderate 
impairment”, and 1.5 SD below the mean score of the control group, as a threshold for 
“severe impairment”. Holmén et al. (2009) used similar cut-off criteria in their study of 
Norwegian adolescents with first-episode psychosis, to describe level of impairment within 
their patient group. Their methods were inspiring to our analyses, since we wanted to explore 
within-group differences in neurocognitive deficits in schizophrenia. Moreover, the cut-off 
scores, 1.0 SD and 1.5 SD below the mean score of the control group were used to investigate 
level of impairment in each individual in the patient group. Number of tests showing 
impairments in each individual profile was identified manually by counting test scores below 
cut-off.     
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RESULTS 
 
Table 1. Demographic and clinical characteristics of patients with schizophrenia and healthy 
controls.  
 
 Patients (n=18) Healthy controls 
(n=18) 
Sex (female) 8 (44.4 %) 8 (44.4 %) 
Hand Dominance (R) 18 (100 %) 17 (99.4 %) 
Age (Y) 21.6 (3.0) 21.2 (3.3) 
Education (Y) 11.4 (2.2) 11.3 (2.2) 
PANSS   
Positive 18.7 (3.6)  
Negative 20.7 (5.4)  
Total 77.2 (16.7)  
Treatment (hospitalised) 12 (66.7 %)  
Duration of untreated psychosis (wk) 62.8 (73.3)  
 
Note: PANSS, Positive and Negative Syndrome Scale. 
 
Demographic characteristics of the patients with schizophrenia spectrum disorders, and 
healthy controls, as well as clinical information of the patient group, are listed in table 1. Age, 
education, PANSS scores, and duration of untreated psychosis in Mean (SD). 
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Table 2. Neuropsychological test results of the MATRICS Consensus Cognitive Battery for 
patients with schizophrenia compared with healthy controls, n=36. 
 
 Patients Controls  
 Mean SD Mean SD t p 
TMT–A 36.1 14.3 28.1 10.4 -1.94 .062 
BACS 47.2 8.5 63.6 12.0 4.75 .000 
HVLT-R 25.7 4.1 28.4 4.7 1.86 .072 
WMS III 18.2 3.4 18.8 3.1 .52 .608 
LNS 12.8 2.5 15.4 3.2 2.73 .010 
Mazes (NAB) 17.8 6.2 23.5 2.3 3.65 .001 
BVMT-R 24.9 5.3 30.2 4.2 3.32 .002 
Category Fluency 20.9 5.6 24.1 6.6 1.58 .125 
CPT-IP 2.2 0.6 2.7 0.4 2.95 .006 
MSCEIT 87.2 11.8 90.6 9.4 .94 .356 
 
Note: TMT-A, Trail Making Test-A; BACS, Brief Assessment of Cognition in Schizophrenia 
(symbol coding); HVLT-R, Hopkins Verbal Learning Test-Revised; WMS, Wechsler 
Memory Scale III (spatial span); LNS, Letter-Number Span; NAB, Neuropsychological 
Assessment Battery; BVMT-R, Brief Visuospatial Memory Test-Revised; CPT-IP, 
Continuous Performance Test, Identical Pairs; MSCEIT, Mayer-Salovey-Caruso Emotional 
Intelligence Test.  
 
The MATRICS Consensus Cognitive Battery (MCCB) was used to examine neurocognitive 
differences between the patient group and the control group. Table 2 summarises the raw 
scores on the subtests of the MCCB. In the patient group, significant impairment was 
discovered in five subtests corresponding to five domains; speed of processing, working 
memory, reasoning and problem solving, visual learning/memory, and attention/vigilance. 
The remaining subtests did not reveal any significant differences between the groups. Gender 
was used as a control variable, and yielded no significant effects concerning between group 
differences, except on the subtest MSCEIT. 
 
Eighteen participants in each group performed the subtests in the MCCB, except the Mazes 
test, where data is missing for one healthy control due to administrative problems. 
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Table 3. Number of patients with schizophrenia demonstrating neurocognitive impairments 
on the subtests of the MCCB, i.e. performance ≥1.0 SD and ≥1.5 SD below the mean of the 
control group, n=18. 
  
 Impairment (≥1.0 SD) Impairment (≥1.5 SD) 
TMT-A 7 (38.9 %) 4 (22.2 %) 
BACS 13 (72.2 %) 8 (44.4 %) 
HVLT-R 7 (38.9 %) 2 (11.1 %) 
WMS III 6 (33.3 %) 1 (5.6 %) 
LNS 11 (61.1 %) 4 (22.2 %) 
Mazes (NAB) 13 (72.2 %) 10 (55.6 %) 
BVMT-R 8 (44.4 %) 7 (38.9 %) 
Category Fluency 5 (27.8 %) 2 (11.1 %) 
CPT-IP 10 (55.6 %) 6 (33.3 %) 
MSCEIT 7 (38.9 %) 4 (22.2 %) 
 
Note: TMT-A, Trail Making Test-A; BACS, Brief Assessment of Cognition in Schizophrenia 
(symbol coding); HVLT-R, Hopkins Verbal Learning Test-Revised; WMS, Wechsler 
Memory  Scale III (spatial span); LNS, Letter-Number Span; NAB, Neuropsychological 
Assessment Battery; BVMT-R, Brief Visuospatial Memory Test-Revised; CPT-IP, 
Continuous Performance Test, Identical Pairs; MSCEIT, Mayer-Salovey-Caruso Emotional 
Intelligence Test. Df = 1. 
 
In order to discover to what extent neurocognitive impairments were present in the patient 
group in our study, a cut off score for moderate impairment was set to 1.0 SD below the mean 
of the control group, and cut off score for severe impairment at 1.5 SD. The percentage of 
patients that performed ≥1.0 SD and ≥1.5 SD below the mean score of the control group on 
each subtest, and thereby show signs of impairment, are displayed in table 3.  
 
Moreover, further examination of level of impairment, revealed that 16 patients (89.9 %) 
displayed moderate impairment on three or more subtests, while 10 (55.6 %) showed 
moderate impairment on five or more subtests. Ten patients (55.6 %) demonstrated severe 
impairment on three or more subtests, while the number was reduced to 4 (22.2 %) when 
number of subtests was increased to five or more. 
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Table 4. Resilience, hope, and self-efficacy scores in the patient group. 
 
 Patients  
   Mean SD n 
CD-RISC 57.1 14.4 15 
HHI 34.6 5.2 18 
GSE 27.8 5.0 18 
 
Note: CD-RISC, Connor-Davidson Resilience Scale; HHI, Herth Hope Index; GSE, General 
Perceived Self-Efficacy Scale. 
 
Data are missing for three of the participants in our patient group on CD-RISC, because the 
instrument was not included in the initial phase of the longitudinal study our data is a part of.  
 
 
 
Table 5. Distribution on variables of daily functioning in the patient group. 
 
 Patients  
 Yes No n 
Employment 8 (44.4 %) 10 (55.6 %) 18 
In education 9 (52.9 %) 8 (47.1 %) 17 
Grocery shopping 9 (52.9 %) 8 (47.1 %) 17 
Shopping own clothes 16 (94.1 %) 1 (5.9 %) 17 
Domestic chores 13 (76.5 %) 4 (23.5 %) 17 
Cooking 14 (82.4 %) 3 (17.6 %) 17 
In a romantic relationship 1 (5.9 %) 16 (94.1 %) 17 
Leisure activities 16 (94.1 %) 1 (5.9 %) 17 
Contact with parents 18 (100 %) 0 18 
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Diagram 1. Number of close friends reported by the participants in the patient group, n=18. 
 
 
 
Together, table 5 and diagram 1 describe daily functioning of participants in the patient 
group. On measures of activities of daily life, except employment, contact with parents, and 
number of friends, data are missing on one patient due to inconsistency in the administration 
of the interview.  
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DISCUSSION 
 
Neurocognitive impairments and the MCCB 
Data from this study discover differences between the patient group and the control group on 
several neurocognitive subtests, included in the MCCB. As presented in the introduction, 
previous studies have demonstrated the reliability and sensitivity of this test battery (Holmén 
et al., 2009; Nuechterlein et al., 2008). The MCCB is useful in detecting neurocognitive 
impairments in the patient group of our interest, where five tests corresponding to five 
domains, reveal significant differences between the groups. Even though five tests 
corresponding to four domains did not demonstrate significant differences, we would expect 
significant differences to be discovered on all the subtests of the MCCB, if the number of 
participants were higher. Based on the Norwegian study measuring neurocognitive 
differences between patients and controls with the MCCB, an exception to our expectation 
might be the measure of social cognition, the MSCEIT, since the usefulness of this test in 
detecting impairments in adolescents with schizophrenia was debated (Holmén et al., 2009). 
Together, these findings suggest that differences in neurocognitive functioning between 
patients with schizophrenia and healthy controls exist in our sample, and that the MCCB is 
useful in detecting these differences.  
 
The five tests discovering differences between the groups correspond to five different 
domains (attention, executive function, learning, working memory, and speed of processing).  
Attention is a complex construct, and in our analyses vigilance, i.e. attention towards a 
relevant object, is measured with CPT-IP (Green, 1998). Our data examining degree of 
impairment in vigilance reveal moderate impairment in 55.6 % of the patient group when 
using a criterion of ≥ 1.0 SD below the mean of the control group. Severe impairment was 
demonstrated in 33.3 % of the patients, when the criterion of ≥ 1.5 SD below the mean of the 
control group, was used. Although attention is a miscellaneous construct, our data imply that 
vigilance is an aspect of attention impaired in patients with schizophrenia, and that the CPT-
IP is useful in detecting the deficits. Despite the low number of participants, the current 
findings of attention deficits in the patient group, supports the broadly accepted agreement 
that many patients with schizophrenia struggle with different aspects of attention (Braff, 
1993). 
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Executive functions involve complex cognitive processing such as planning, evaluating 
possible consequences of actions, and executing behaviour, and are considered important for 
responding and adapting to the surroundings (Rund, 2002). Impairments in executive 
functions are demonstrated in the patient group by our data, with moderate impairment in 
72.2 % of the patients when a criterion of ≥ 1.0 SD below the mean of the control group is 
used, and severe impairment displayed in 55.6 % of the patient group when using a criterion 
of ≥ 1.5 SD. This is in line with previous findings that have proposed executive function 
deficits as a core feature in schizophrenia (Weickert et al., 2000). Our results may support 
that the MCCB, or more specifically the Mazes Test, is successful in detecting impairments 
in executive functions in patients with schizophrenia. At the same time, we cannot conclude 
whether the differences between the groups in reasoning and problem solving are discovered 
due to the sensitivity of the test or if it may implicate profound impairment in the patient 
group, since our study is not of psychometric character. 
 
On the domain of working memory significant differences between the groups were detected 
by the LNS, a test measuring the verbal part of working memory. However, no significant 
differences were discovered in the visual part of working memory, measured with the WMS-
III. The same phenomenon was observed on the domain of learning and memory, where the 
BVMT-R, tapping visual learning, revealed significant differences between patients and 
controls, while the HVLT-R, measuring verbal learning, did not. These findings only partly 
support our expectations, that significant differences would be detected on all neurocognitive 
subtests of the MCCB, with the possible exception of the MSCEIT. However, based on 
previous research, we would expect significant differences on all subtests of working 
memory and memory and learning to be discovered if the number of participants were higher 
(Gold et al., 1992; Gur et al., 2000; Keefe, 2000; Wobrock et al., 2009). 
 
Two of the tests measuring speed of processing, as well as the measures of verbal learning 
and visual working memory, did not reveal significant differences between patients and 
controls, as opposed to our expectations, based on extensive work by the MATRICS 
Neurocognition Committee (Green et al., 2004a; Green et al., 2004b; Kern et al., 2004; Kern 
et al., 2008; Nuechterlein et al., 2008). One possible interpretation of our results might be that 
in fact no differences on these domains exist between the groups in our study. Hence, the 
significant difference found in scores on the BACS might be due to random errors, since the 
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other tests on the domain of speed of processing did not reveal significant differences. 
However, the high percentage of patients (72.2 %) demonstrating moderate impairment in 
speed of processing measured with the BACS, makes us question the interpretation of 
random errors. Moreover, patients suffering from schizophrenia differ to a large extent on 
measures of neurocognition and functional outcome (Green, 1998; Jobe & Harrow, 2005), 
which should also be considered a reason for not discovering differences between groups in a 
small sample like ours. Furthermore, the distribution is dependent on each individual score. 
Performance above or below the mode characterised as extreme scores, will have a major 
influence on the mean and create even larger within-group differences. In studies with a low 
number of participants, the mean is sensitive to extreme scores. To sum up, interpretations of 
the non-significant differences are dependent on the small sample, and based on previous 
findings we would expect significant differences to be discovered between the patients and 
controls on all subtests of the MCCB, when applied to a larger sample (Holmén et al., 2009; 
Kern et al., 2008; Nuechterlein et al., 2008).  
 
No significant differences between the two groups were discovered on the domain of social 
cognition, measured with the MSCEIT, which is a replication of what was found in the single 
published Norwegian study concerning the MATRICS initiative (Holmén et al., 2009). A 
reason for our results might be that the domains selected when the MCCB was developed, 
were chosen on the basis of thorough factor-analyses, except the domain of social cognition, 
which was selected on experts’ ratings alone (Nuechterlein et al., 2004). Another reason why 
we question the use of the MSCEIT in differentiating between patients and controls is that 
this test was chosen partly due to lack of alternative measures of social cognition 
(Nuechterlein et al., 2008). Additionally, Holmén et al. (2009) suggest two possible 
explanations why no differences between their two groups were detected. First, it might be 
that both groups performed well, which is supported by an indication of no differences 
between patients with schizophrenia and controls on knowledge on how to act in social 
situations, and that problems are made explicit when the knowledge has to be taken into use 
(Vaskinn et al., 2008). The second reason might be that both groups performed poorly, since 
the scores of the control group are below of what might be expected compared to the 
American norms for the young adult group. These interpretations might also be expected to 
be plausible to our results, but the lack of standardised norms for the Norwegian population, 
makes it difficult to confirm or invalidate either.  
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Furthermore, we also question the use of the MSCEIT because the fixed alternatives might 
not disclose the reasoning that leads the participants to their choice, and thereby the 
investigation of the entire complexity of social cognition will be hampered (C. Mohn, 
personal communication, April 24, 2010). Also, some alternatives might be incorrect 
according to the test question, but still be advantageous for the agent in the story in another 
context. Therefore it would be interesting to score the participants on the basis of their 
reasoning, their evaluations of different aspects of the stories, and their interpretations of the 
consequences of different actions. Additionally, it would also be informative to observe their 
social skills in a situation that requires interaction with others. Role-play, might be such an in 
vivo measurement of social cognition (Bellack, Brown, & Thomas-Lohrman, 2006).  
 
Degree of neurocognitive impairment 
Previous studies have revealed large individual differences in neurocognitive functioning and 
degree of impairment, amongst patients diagnosed with schizophrenia (Holmén et al., 2009; 
Palmer et al., 1997; Rund, 1998). Despite the variation in degree of neurocognitive 
impairment in the group, the majority probably experience an alteration from their premorbid 
level (Green, 1998). Findings from our data set support this heterogeneity in neurocognitive 
functioning. Approximately 90 % of the patients display moderate impairment on three or 
more tests, while the percentage was reduced to 55.6 % showing moderate impairment on 
five or more tests. Moreover, 55.6 % exhibit severe impairment on three or more tests, and 
scarcely 23 % of the patient group show severe impairment on five or more subtests. These 
results illustrate that a large amount of the patient group, struggle to some extent in terms of 
neurocognitive functioning. Furthermore, only a minor part of our patient group displays 
severe impairment on more than half of the subtests of the MCCB. In line with previous 
research, the amount of patients demonstrating neurocognitive impairments in our study, as 
well as the degree of impairment, varies according to the criteria of impairment in use 
(Palmer et al., 1997). Overall, this suggests that psychoses and schizophrenia may exist 
independently of profound neurocognitive deficits. Moreover, given these in-group 
differences, the sensitivity of a neurocognitive test battery is of major importance. 
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Resilience, hope, and self-efficacy 
Our study also applied measures of resilience, hope, and self-efficacy, with the intention of 
describing what characterises young adults with first-episode psychosis. Our data show that 
the patients’ perceived degree of resilience measured with the CD-RISC, is considerably 
lower than what has been found in the general population (Connor & Davidson, 2003). 
Moreover, the scores of our patients are also below of what has been found in a group of 
outpatients suffering from other mental illnesses. This implies that the patients with 
schizophrenia differ from both the general population and the outpatients with other 
diagnoses of mental illness in terms of resilience. A reason for this might be variations in the 
quantity and quality of stress experienced, and the ability to handle the stress they are 
exposed to. As presented in the introduction, resilience has been demonstrated to be 
modifiable by treatment in mental illness such as General Anxiety Disorder (GAD) (Connor 
& Davidson, 2003). It would be fruitful to investigate if resilience scores may also improve 
with treatment in patients suffering from schizophrenia.  
 
The scores of hope in our study, measured with the HHI, are slightly below the mean in the 
general population (Rustøen et al., 2003). This indicates that the patients’ experienced degree 
of hope is relatively preserved shortly after the outbreak of a first-episode psychosis. One 
might expect that the perceived degree of hope diminish proportionately with the severity of 
illness, but our data imply that a correlation between severity of illness and decreased degree 
of hope do not necessarily exist. In line with this, research has suggested that the individual’s 
subjective view of health is a more important predictor of hope, than the presence of chronic 
disease itself (Rustøen et al., 2003). 
 
Self-efficacy scores in the patient group, measured with the GSE in our study, are shown to 
be scarcely below the mean in the general population (Scholz et al., 2002). Receiving a 
diagnosis such as schizophrenia appears not to diminish the perceived belief of coping 
abilities in our patient group.  
  
Researchers have not yet systematically investigated the connection between resilience, hope, 
self-efficacy, and schizophrenia (A. K. Torgalsbøen, personal communication, April 14, 
2010), but it seems useful to look closer at resources within the individual to gain information 
on factors contributing to remission and recovery. First of all, strengthening a modifiable 
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quality already present in the individual represents a qualitatively different way of 
approaching the issue of remission and recovery, and would be a useful addition to the main 
focus of removing unwanted symptoms. This view will also provide the patients with agency, 
and might offer the opportunity to affect their outcome. Secondly, the inclusion of these 
measures represents another way of describing this patient group, with a possibility of 
discovering new characteristics of patients who recover. Furthermore, these characteristics 
could be of interest in developing efficient interventions and tailoring treatment to the 
individual in order to promote recovery in schizophrenia. Data from our study describe the 
patient group in terms of resilience, hope, and self-efficacy at baseline level. Measures across 
longer periods of time will generate new knowledge on how the variables change during the 
course of the illness. It will then be possible to evaluate the importance of these factors in 
relation to treatment and recovery in schizophrenia.  
 
Daily functioning 
Information on daily functioning demonstrated that 45 % of the patients are employed and 
over 50 % are attending high school or college, at baseline level. This does not mean that 
 95 % are either working or attending school, instead some of the participants reply 
affirmative on both questions. Twelve of the participants (66.7 %) were hospitalised at the 
time of testing, and we assume that the majority of these patients were either on sick leave at 
the time of testing or unemployed. However, we do not have access to precise data 
concerning information on employment or educational status, due to inconsistency and 
inexact wording of the questions in the interview. Therefore we are uncertain if the status 
reported by the patients represents their status before onset of psychosis, if they are employed 
but have a sick note, or if they are actually working. Moreover, one third of our patients  
(33.3 %) are outpatients at the time of testing. We must consider the possibility that some of 
these patients manage to function in work or educational situations, perhaps with the aid of 
vocational rehabilitation, “active” sick notes, and adjusted work loads, not covered by 
dichotomous variables like the ones used in our study. To sum up, interpretation of the results 
must be carried out in a careful manner.  
 
Our data implicate that some of the patients might be able to function in working or learning 
situations, despite our results of impairments in the group on several neurocognitive domains, 
assessed with the MCCB. In other words, the findings suggest a possibility of retaining parts 
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of daily functioning when receiving a diagnosis of a mental illness traditionally associated 
with a chronic course. However, researchers have discovered rates of 10 % and 14.5 % in 
competitive employment activity in patients with schizophrenia at baseline level (Mueser et 
al., 2001; Rosenheck et al., 2006). When considering research on employment rates in 
patients with schizophrenia, we would expect our material to reflect approximately the same 
percentages at baseline level, consonant with the part of our data showing that the majority of 
the patients are hospitalised.  
 
Even though some persons suffering from schizophrenia might be working or studying, we 
would expect them to struggle somewhat when performing tasks requiring neurocognitive 
processing based on our findings on the degree of neurocognitive impairment in the group. 
Supporting this are studies demonstrating decreased neurocognitive functioning in patients 
with schizophrenia, such as neuropsychologically unimpaired monozygotic twins with 
schizophrenia who performed more poorly than their unaffected twin (Goldberg et al., 1990). 
Furthermore, it is expected that cognitive enhancing interventions would be beneficial for 
most patients with the diagnosis (Green, 1998; Nuechterlein et al., 2008). This underlines the 
importance of assessing neurocognitive functioning with a sensitive test battery to discover 
the patients’ strengths and weaknesses. In order to adjust working or learning situations, 
clinicians may introduce techniques to enhance learning, memory, and concentration, as well 
as normalising challenging difficulties, such as helping patients to acknowledge that they 
might need extra time due to reduced speed of processing. In other words, assessing 
neurocognitive functioning might be helpful in facilitating utilisation of patients’ abilities and 
potential.  
 
Our data concerning shopping own clothes, performing domestic chores, and cooking show 
that nearly all patients are themselves responsible for these tasks. Only half of the patient 
group does their own grocery shopping, but this might be due to their living situation, since 
more than half of these young adults are living with their parent(s). Together, this could mean 
that our patient group is able to manage their own household without being dependent on 
help from others and that parts of their daily functioning are preserved. However, we must 
consider the amount of patients hospitalised at the time of interviewing. The questions could 
be interpreted as an enquiry of independent living when not hospitalised and before the onset 
of illness. Conversely, what was reported could reflect chores carried out inside the 
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institution with help from others, in a safer environment than outside on their own. Both these 
ways of interpreting the questions could potentially overestimate the ability to keep a 
household. Additionally, the high percentages might also reflect skewness in the sample. Our 
sample might not be representative for the entire patient population, and perhaps the results 
reflect their relatively high level of independent living. 
 
Information on relational functioning was obtained in terms of questions concerning romantic 
relationships and number of friends. Only one of the patients was engaged in a romantic 
relationship and 16 of 18 patients reported having three or fewer friends at the time of testing. 
These findings might indicate that the patients in our study struggle to interact and relate to 
others, and that social functioning is challenging. Also, the findings might be seen as a 
preference in the group to interact with few close friends rather than a group, which in turn 
might be a reflection of lack of social abilities. Knowledge on how to relate to a group of 
people might be present in the patients, but it could be difficult and complex to actually 
perform and adapt to social settings (Vaskinn et al., 2008). Such performance requires 
flexibility and the ability to simultaneously process a large amount of stimuli. Our patients do 
not differ from the controls on social cognition measured with the MSCEIT, but we assume 
that difficulties in interactions and social situations might be reflected in number of friends 
and few engagements in romantic relationships. Information on relational functioning is not 
available for the control group, and thus this possible interpretation remains a speculation.  
 
Another aspect that might support our interpretation of the reported relational functioning 
could be the level of anxiety and depression often experienced by patients with 
schizophrenia. These affects are included as negative symptoms measured with the PANSS. 
The mean score on the scale of negative symptoms in our patient group is within the 40th 
percentile according to a sample of 101 patients with schizophrenia, indicating that these 
symptoms are present in a mild to moderate degree in our patients (Kay et al., 1987). 
Withdrawal could also be influenced by scores on positive symptoms such as paranoia, which 
are included in the scale of positive symptoms in the PANSS. The patient group in our study 
has a mean score within the 55th percentile according to the same sample, indicating a 
moderate degree of positive symptoms. These scores might reflect the difficulties in daily 
functioning, particularly in terms of relational functioning.  
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Moreover, personality dispositions might be another explanation to consider. Introversion and 
neuroticism can be part of the motivation why some people choose to stay in environments 
with fewer stimuli than others. Research also supports that these personality traits might play 
a part in the social withdrawal in individuals with a diagnosis of schizophrenia (Berenbaum 
& Fujita, 1994). 
 
The small sample of patients in our study makes it difficult to generalise, and we do not know 
if our patient group is representative for the entire patient population suffering from 
schizophrenia. As previously mentioned, several were hospitalised at the time of testing, and 
this probably affected the information obtained on daily functioning. We assume that the 
patients with relatively preserved daily functioning also demonstrate few neurocognitive 
deficits. However, since we do not have access to Norwegian norms and therefore lack 
composite scores, it is difficult to examine these correlations. Variables of daily functioning 
will be interesting to study over the course of time, both isolated and in relation to 
neurocognitive functioning, to give a more detailed description of this patient group. 
 
Limitations of the present study 
Several limitations should be discussed in relation to the findings of our study. First of all, the 
low number of participants due to the fact that the recruitment of subjects to the main study is 
still in progress, must be considered. However, when doing research on this patient group one 
must consider the prevalence of persons suffering from this mental illness, which is believed 
to be stable across different populations and cultures, at approximately 1 % of the total 
population (Combs & Mueser, 2007). Furthermore, another selection criterion in our study is 
that the psychosis must be the first experienced by our participants, which limits our possible 
selection even further, since the annual incidence rates of schizophrenia has been found in the 
range of 0.16-0.40 pr 1000 population (Jablensky, 2000). Geographical limitations, in form of 
the small size of catchment area of the main study, is another factor contributing to a low 
number of participants. Recruitment from other regions than the south-eastern part of 
Norway, would be both time consuming and economically unfeasible. Keeping this in mind, 
a low number of participants in the patient group should be expected, and if this group is to 
be studied, one must proceed with the research despite the low number of possible 
participants. To sum up, at this stage the small sample hampers the possibility of drawing 
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conclusions and making generalisations, but the research will nevertheless provide us with 
valuable information on the particular group in focus.  
 
According to the main purpose of this thesis, we expected differences to be discovered on all 
subtests measured with the MCCB. Reasons why differences were not detected on all subtests 
might be due to a number of factors. However, the most plausible explanation for not 
discovering expected differences in all neurocognitive tests seems to be the low number of 
participants. More participants in the patient group would strengthen the statistical power of 
the analyses and the confidence with which conclusions could be made. Moreover, there 
would be a reduced risk of randomised influence on the results, as well as decreased impact 
of statistical outliers and extreme scores. Therefore we must be careful not to underestimate 
the sensitivity of the subtests that did not reveal significant differences between  patients with 
schizophrenia and healthy controls. 
 
The use of raw scores in our data analyses makes it impossible to compare both patient group 
and control group with others of the same age. A lack of standardised data also prevents the 
use of composite scores, which is thought to be more ecologically valid measures and show 
higher correlations to functional outcome than single neurocognitive measures (Green, 1996). 
A sum of several neurocognitive domains probably generates a more reliable basis for 
generalisations and more accurate assumptions concerning everyday life and daily 
functioning.  
 
A further limitation following the use of raw scores is being unable to control for premorbid 
intellectual abilities, by using WAIS-III scores as a control variable when examining 
differences in neurocognitive functioning between patients and controls. This would have 
been an advantage, providing more detailed information and facilitating a more precise 
conclusion. Perhaps large individual differences were present both within the patient group 
and between patients and controls, before the onset of illness. Despite this, Holmén et al. 
(2009) argue that an accurate measure of premorbid intellectual abilities will not be available 
after the onset of illness. Also, the prodromal phase and the development of schizophrenia are 
known to be gradual, and it is often difficult to determine the exact time of onset (Møller, 
2005). Studies show that individuals suffering from schizophrenia display signs of 
neurocognitive deficits already at an early age (Bilder et al., 2006; Erlenmeyer-Kimling et al., 
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2000). With this in mind, the validity of measures of premorbid intellectual abilities is 
questioned and the disadvantage of our study’s lack of such measures seems less significant. 
 
If composite scores were available, we would also have examined the correlation between 
neurocognitive functioning and duration of psychosis. As described in table 1, duration of 
psychosis varied from four weeks to five years, which could possibly have affected 
performance on the MCCB. However, Rund et al. (2007) discovered that the duration of 
psychosis was not related to neurocognitive functioning in schizophrenia, implying that other 
analyses than the correlation between neurocognition and duration of psychosis would be of 
greater interest. Furthermore, an analysis of the correlation between degree of symptoms, 
measured with the PANSS, and composite scores from the MCCB, would be desirable, but 
not possible, since we do not have access to composite scores. 
 
Psychopharmacological treatment is a factor with possible influence on neurocognitive 
performance in the patient group, potentially affecting our results. All but one patient 
received psychopharmacological treatment at the time of testing, and consequently a 
comparison between medicated and non-medicated individuals within the patient group is 
hampered. Thus, we are not able to determine if an influence of medical treatment is present, 
and if so, the value of this influence. 
 
A risk following the use of self-report scales, such as the CD-RISC, the HHI, and the GSE, 
could be that the scores might be influenced by a psychotic state of mind and therefore be 
vulnerable to the patient’s degree of insight. The reliability of self-reports may be 
strengthened if the patient’s state is stabilised and the positive symptoms are repressed with 
antipsychotic medication.  
 
Another limitation that should be discussed is the basis for comparison on the CD-RISC, the 
HHI, and the GSE. As mentioned in the method section in this thesis, researchers have 
discovered norms for comparison in the general population for these instruments. In addition, 
a mean of outpatients with mental illness, such as depression and anxiety, is used in relation 
to the CD-RISC. However, the groups used for comparison are not matched with our patient 
group, and potentially influential variables are not controlled for, such as gender, age, and 
severity of illness. Also, these measures have not been used on populations suffering from 
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schizophrenia, and therefore no comparisons matched on the diagnosis are available. 
Moreover, we do not know if these measures are useful in revealing information on 
individuals with schizophrenia and their path towards recovery. 
 
It is assumed that a control group whose participation is dependent on their own initiative, i.e. 
answering an advertisement, will be motivated in a different way than the patient group. 
These motivational differences are thought to affect the performance of the control group. In 
addition, volunteering controls often have another level of socioeconomic background than 
the patient group, which in turn may affect their performance.  
 
Clinical implications and future research 
In spite of these limitations, the study reveals several significant neurocognitive differences 
between the groups, corresponding to five distinct neurocognitive domains. Hence, this could 
be seen as supporting the use of the MCCB in detecting differences between patients and 
controls. Our data support the intended purpose of the test battery, namely that it could serve 
as a useful and appropriate tool in discovering neurocognitive impairments in patients 
suffering from schizophrenia. We predict that the MCCB will prove to be a helpful 
instrument for both researchers and clinicians in Norway, not only to elucidate impairments 
and resources, but also to help professionals adjust interventions and improve the patients’ 
daily functioning. 
 
As discussed in this thesis, heterogeneity in terms of neurocognition is common in the patient 
group. Assessing each individual who receives a diagnosis of schizophrenia with a cognitive 
test battery, like the MCCB, will have implications for treatment, and important information 
concerning the potential utility of interventions may be discovered. A thorough 
neuropsychological examination will disclose both the patient’s resources and deficits. Thus, 
clinical use of the MCCB will aim at transforming the test results into practical information, 
developing and implementing helpful strategies, and thereby facilitating optimal 
neurocognitive and daily functioning in patients with schizophrenia despite their diagnosis. 
Patients may experience a more successful adaptation and integration to society with help of 
interventions in their daily life, on the basis of the neuropsychological assessment.  
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Information obtained on daily functioning illustrates heterogeneity in the patient group in our 
study, indicating the possibility of somewhat preserved abilities to function in everyday life 
after the onset of psychosis. Due to methodological inconsistencies, conclusions cannot be 
made. Still, in relation to the concept of recovery, which now includes social adaptation, 
working abilities, and daily functioning, as well as decrease in symptoms (Frese et al., 2009; 
Liberman et al., 2002), a description of this patient group in terms of daily functioning is 
useful. 
   
Our study has used preliminary data that are part of a longitudinal study following patients 
for ten years. At baseline level, it is not possible to predict outcome or to draw conclusions 
concerning the process of recovery. When the data collection is complete and standardised 
scores of the Norwegian population are available, reliable information on the course of 
schizophrenia will enable the identification of possible predictors of recovery. On the basis of 
the heterogeneity in degree of impairment discovered in our study, we expect the patients 
showing few signs of neurocognitive impairments to have a more positive prognosis than 
those who struggle. In other words, neurocognition could be identified as a protecting factor, 
if a correlation between neurocognition and recovery exists. 
 
Furthermore, we assume that resilience, hope, and self-efficacy, will covariate with recovery. 
Indeed, some researchers have discovered that the hope contributing to recovery is in fact the 
individual’s own belief that recovery is possible (Jacobson & Greenley, 2001). This implies a 
responsibility for health care workers of inducing hope that recovery is possible when an 
individual receives a diagnosis of schizophrenia. More research on such concepts and their 
correlation to recovery will provide professionals with information on characteristics of 
persons who recover. In addition, more accurate predictions on outcome will be available, 
and interventions in therapy may be tailored accordingly. 
 
Conclusion 
We discovered significant differences between patients with schizophrenia and healthy 
controls on several neurocognitive subtests of the MCCB. Moreover, heterogeneity in the 
patient group was discovered on degree of impairment in neurocognitive functioning, as well 
as on variables of daily functioning. Our thesis examining measures of neurocognition, 
resilience, hope, and self-efficacy, and information of daily functioning, is yet another 
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scientific contribution concerned with promoting recovery and enhancing quality of life in 
patients with schizophrenia. Researchers aim to improve functional outcome by discovering 
modifiable factors facilitating recovery, founded in the reformed, multifaceted concept of 
recovery. This positive approach provides patients, relatives, and professionals with hope and 
motivation to continue the struggle towards a life of physical, mental, and social well-being 
for individuals with a diagnosis of schizophrenia. 
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